<p>瑞金制药（NASDAQ:REGN - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员从 “买入” 评级下调至 “持有” 评级。</p>
<ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
<p>其他几位股票研究分析师也对该公司发表了看法。汇丰全球研究在 11 月 24 日的研究报告中将瑞金制药的评级上调至 “强力买入”。古根海姆在 10 月 29 日的研究报告中将瑞金制药的目标价从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。汇丰在 11 月 24 日的报告中开始覆盖瑞金制药的股票，设定了 “买入” 评级和 255.00 美元的目标价。BMO 资本市场在 12 月 4 日的研究报告中将瑞金制药的目标价从 725.00 美元上调至 850.00 美元，并给予该股票 “跑赢大盘” 评级。最后，加拿大皇家银行在 10 月 29 日的研究报告中将瑞金制药的目标价从 704.00 美元上调至 708.00 美元，并给予该股票 “行业表现” 评级。三位投资分析师给予该股票 “强力买入” 评级，十五位给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，瑞金制药的平均评级为 “适度买入”，共识目标价为 779.45 美元。</p>
<p><strong>阅读我们关于 REGN 的最新股票报告</strong></p>
<h2>瑞金制药的价格表现</h2>
<ul>
<li>5 个医疗保健股票值得关注，因为行业轮换正在全面展开</li>
</ul>
<p>NASDAQ REGN 的股票在周五以 767.96 美元开盘。瑞金制药的 1 年低点为 476.49 美元，1 年高点为 790.98 美元。该股票的市值为 807.1 亿美元，市盈率为 18.39，市盈率/增长比率为 2.15，贝塔值为 0.37。公司的 50 日移动平均线为 682.40 美元，200 日移动平均线为 599.63 美元。公司的债务与股本比率为 0.09，流动比率为 4.06，速动比率为 3.33。</p>
<p>瑞金制药（NASDAQ:REGN - 获取免费报告）最近在 10 月 28 日发布了季度财报。这家生物制药公司报告本季度每股收益为 11.83 美元，超出共识预期的 9.73 美元，超出幅度为 2.10 美元。瑞金制药的净利润率为 32.13%，股本回报率为 13.76%。该公司在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。去年同期，该公司每股收益为 12.46 美元。瑞金制药的季度收入较去年同期增长了 0.9%。平均而言，卖方分析师预计瑞金制药在当前年度的每股收益将达到 35.92 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>大跌者：3 只接近 1 年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>在其他瑞金制药的新闻中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。该股票以平均 651.43 美元的价格出售，总价值为 280,766.33 美元。出售完成后，副总裁持有公司 4,233 股，价值 2,757,503.19 美元。这代表其持股减少了 9.24%。该交易在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。该股票以平均 654.27 美元的价格出售，总交易额为 4,252,755.00 美元。出售后，董事持有公司 2,352 股，价值约 1,538,843.04 美元。该交易使其持股减少了 73.43%。该交易的披露在 SEC 文件中可获得。目前，7.02% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>最近几家对冲基金和其他机构投资者增加或减少了对该公司的持股。Keel Point LLC 在第三季度购买了瑞金制药的新股份，价值约 251,000 美元。CTC 替代策略有限公司在第三季度购买了瑞金制药的新股份，价值 307,000 美元。Allworth Financial LP 在第三季度将其在瑞金制药的持股增加了 50.5%。Allworth Financial LP 现在拥有 1,496 股生物制药公司的股票，价值 841,000 美元，此前在上个季度购买了 502 股。IFP Advisors Inc 在第三季度将其在瑞金制药的持股增加了 14.2%。IFP Advisors Inc 现在拥有 1,405 股生物制药公司的股票，价值 790,000 美元，此前在上个季度购买了 175 股。最后，瑞士人寿资产管理有限公司在第三季度将其在瑞金制药的持股增加了 112.0%。瑞士人寿资产管理有限公司现在拥有 23,658 股生物制药公司的股票，价值 13,302,000 美元，此前在上个季度购买了 12,500 股。目前，83.31% 的股票由机构投资者持有。</p>
<h2>关于瑞金制药</h2>
<p>（获取免费报告）</p>
<p>瑞金制药公司（NASDAQ: REGN）是一家总部位于美国的生物技术公司，成立于 1988 年，总部位于纽约州塔里敦。该公司专注于发现、开发、生产和商业化用于治疗严重医疗条件的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
<p>瑞金以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>股票情绪分析：它是如何运作的</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>初学者如何阅读股票图表</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在再生元制药吗？</h2>
<p>在考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
<p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>华尔街禅将再生元制药的评级从 “买入” 下调至 “持有”。其他分析师的意见各异，有的将评级上调至 “强烈买入”，而有的则调整了目标价格。该股票的共识评级为 “适度买入”，目标价格为 779.45 美元。近期的内部交易和机构投资也受到关注</p>

<p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.</p>
<div class="lb-trans"><p>瑞金制药（NASDAQ:REGN - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员从 “买入” 评级下调至 “持有” 评级。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药物的投资</li>
</ul>
</div><p>Several other equities research analysts have also weighed in on the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Monday, November 24th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a &#34;buy&#34; rating and a $255.00 target price on the stock. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada boosted their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a &#34;sector perform&#34; rating in a research note on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $779.45.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对该公司发表了看法。汇丰全球研究在 11 月 24 日的研究报告中将瑞金制药的评级上调至 “强力买入”。古根海姆在 10 月 29 日的研究报告中将瑞金制药的目标价从 815.00 美元上调至 865.00 美元，并给予该公司 “买入” 评级。汇丰在 11 月 24 日的报告中开始覆盖瑞金制药的股票，设定了 “买入” 评级和 255.00 美元的目标价。BMO 资本市场在 12 月 4 日的研究报告中将瑞金制药的目标价从 725.00 美元上调至 850.00 美元，并给予该股票 “跑赢大盘” 评级。最后，加拿大皇家银行在 10 月 29 日的研究报告中将瑞金制药的目标价从 704.00 美元上调至 708.00 美元，并给予该股票 “行业表现” 评级。三位投资分析师给予该股票 “强力买入” 评级，十五位给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，瑞金制药的平均评级为 “适度买入”，共识目标价为 779.45 美元。</p>
</div><p><strong>Read Our Latest Stock Report on REGN</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 REGN 的最新股票报告</strong></p>
</div><h2>Regeneron Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>瑞金制药的价格表现</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 个医疗保健股票值得关注，因为行业轮换正在全面展开</li>
</ul>
</div><p>Shares of NASDAQ REGN opened at $767.96 on Friday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $790.98. The stock has a market capitalization of $80.71 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.15 and a beta of 0.37. The company's 50-day moving average is $682.40 and its 200 day moving average is $599.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.</p>
<div class="lb-trans"><p>NASDAQ REGN 的股票在周五以 767.96 美元开盘。瑞金制药的 1 年低点为 476.49 美元，1 年高点为 790.98 美元。该股票的市值为 807.1 亿美元，市盈率为 18.39，市盈率/增长比率为 2.15，贝塔值为 0.37。公司的 50 日移动平均线为 682.40 美元，200 日移动平均线为 599.63 美元。公司的债务与股本比率为 0.09，流动比率为 4.06，速动比率为 3.33。</p>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same period last year, the business posted $12.46 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up .9% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.</p>
<div class="lb-trans"><p>瑞金制药（NASDAQ:REGN - 获取免费报告）最近在 10 月 28 日发布了季度财报。这家生物制药公司报告本季度每股收益为 11.83 美元，超出共识预期的 9.73 美元，超出幅度为 2.10 美元。瑞金制药的净利润率为 32.13%，股本回报率为 13.76%。该公司在本季度的收入为 37.5 亿美元，而分析师预期为 35.7 亿美元。去年同期，该公司每股收益为 12.46 美元。瑞金制药的季度收入较去年同期增长了 0.9%。平均而言，卖方分析师预计瑞金制药在当前年度的每股收益将达到 35.92 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大跌者：3 只接近 1 年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company's stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm's stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他瑞金制药的新闻中，副总裁 Jason Pitofsky 在 11 月 7 日的交易中出售了 431 股公司的股票。该股票以平均 651.43 美元的价格出售，总价值为 280,766.33 美元。出售完成后，副总裁持有公司 4,233 股，价值 2,757,503.19 美元。这代表其持股减少了 9.24%。该交易在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，董事 Christine A. Poon 在 10 月 29 日的交易中出售了 6,500 股公司的股票。该股票以平均 654.27 美元的价格出售，总交易额为 4,252,755.00 美元。出售后，董事持有公司 2,352 股，价值约 1,538,843.04 美元。该交易使其持股减少了 73.43%。该交易的披露在 SEC 文件中可获得。目前，7.02% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Keel Point LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $251,000. CTC Alternative Strategies Ltd. bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $307,000. Allworth Financial LP lifted its stake in Regeneron Pharmaceuticals by 50.5% in the 3rd quarter. Allworth Financial LP now owns 1,496 shares of the biopharmaceutical company's stock worth $841,000 after purchasing an additional 502 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 14.2% during the 3rd quarter. IFP Advisors Inc now owns 1,405 shares of the biopharmaceutical company's stock valued at $790,000 after purchasing an additional 175 shares during the last quarter. Finally, Swiss Life Asset Management Ltd grew its position in shares of Regeneron Pharmaceuticals by 112.0% during the third quarter. Swiss Life Asset Management Ltd now owns 23,658 shares of the biopharmaceutical company's stock valued at $13,302,000 after purchasing an additional 12,500 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>最近几家对冲基金和其他机构投资者增加或减少了对该公司的持股。Keel Point LLC 在第三季度购买了瑞金制药的新股份，价值约 251,000 美元。CTC 替代策略有限公司在第三季度购买了瑞金制药的新股份，价值 307,000 美元。Allworth Financial LP 在第三季度将其在瑞金制药的持股增加了 50.5%。Allworth Financial LP 现在拥有 1,496 股生物制药公司的股票，价值 841,000 美元，此前在上个季度购买了 502 股。IFP Advisors Inc 在第三季度将其在瑞金制药的持股增加了 14.2%。IFP Advisors Inc 现在拥有 1,405 股生物制药公司的股票，价值 790,000 美元，此前在上个季度购买了 175 股。最后，瑞士人寿资产管理有限公司在第三季度将其在瑞金制药的持股增加了 112.0%。瑞士人寿资产管理有限公司现在拥有 23,658 股生物制药公司的股票，价值 13,302,000 美元，此前在上个季度购买了 12,500 股。目前，83.31% 的股票由机构投资者持有。</p>
</div><h2>About Regeneron Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于瑞金制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.</p>
<div class="lb-trans"><p>瑞金制药公司（NASDAQ: REGN）是一家总部位于美国的生物技术公司，成立于 1988 年，总部位于纽约州塔里敦。该公司专注于发现、开发、生产和商业化用于治疗严重医疗条件的药物。公司结合实验室研究、临床开发和内部生产，推进多个治疗领域的生物治疗管线。</p>
</div><p>Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.</p>
<div class="lb-trans"><p>瑞金以其专有的药物发现技术而闻名，包括其 VelocImmune 平台，该平台用于生成完全人源的单克隆抗体。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Insider Trading - What You Need to Know</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>股票情绪分析：它是如何运作的</li>
<li>耐克盈利超预期，但在中国市场面临挑战并遭遇关税</li>
<li>初学者如何阅读股票图表</li>
<li>人工智能热潮是泡沫吗？这两只分红股票表示不是</li>
<li>内幕交易 - 你需要知道的事项</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

再生元制药（NASDAQ:REGN）被华尔街 Zen 下调至持有评级